Daily Archives: June 17, 2020

doTERRA Becomes the First Global Aromatherapy and Essential Oils Company to Join Research Institute for Fragrance Materials

Partnership will pioneer advanced essential oil research

PLEASANT GROVE, Utah, June 17, 2020 (GLOBE NEWSWIRE) — doTERRA today announced that it has been accepted as a supporting member of the world-renowned Research Institute for Fragrance Materials (RIFM). As the leading global aromatherapy and essential oils company, doTERRA was granted membership based on a unanimous vote from the organization’s board of directors. RIFM also invited doTERRA scientists to contribute their essential oils’ knowledge and expertise as part of the organization’s natural complex substances working group.

RIFM’s purpose is to gather and analyze scientific data, engage in testing and evaluation, distribute information, cooperate with official agencies, and encourage uniform safety standards related to the use of fragrance ingredients.

“Our reputation for the relentless pursuit of purity fostered a relationship between RIFM and doTERRA’s sourcing team, which led to the decision to pursue membership in the organization,” said Dr. Russell J. Osguthorpe, doTERRA’s chief medical officer. “This partnership is part of an initiative to perform safety assessments on natural complex substances, such as essential oils. RIFM produces the most authoritative and comprehensive fragrance safety evaluations in the world. Together, we will improve the worldwide understanding of the science and safety behind essential oils, as well as their uses aromatically, topically and internally.”

As members, doTERRA will have access to RIFM’s comprehensive database on fragrance and flavor ingredients, which provides upwards of 70,000 references that include more than 135,000 human health and environmental studies on more than 6,000 materials.

An independent expert scientific panel reviews all of RIFM’s research, and its conclusions form the basis for the standards set by the International Fragrance Association (IFRA). Using the most current, globally-recognized guidelines, RIFM has to date completed panel-approved safety assessments for more than 85% of the current volume of use by the fragrance industry.

“We are an organization that firmly believes that we can do so much better with the safety and understanding of natural complex substances when we bring more resources to the table and expert voices to the discussion,” said RIFM’s President, James C. Romine, PhD. “doTERRA offers a unique and valuable perspective to RIFM, and we look forward to its scientists’ ongoing contributions to our working group.”

About doTERRA

dōTERRA® International is an integrative health and wellness company and the world leader in the Global Aromatherapy and Essential Oils market. dōTERRA sources, tests, manufactures and distributes CPTG Certified Pure Therapeutic Grade® essential oils and essential oil products to over eight million dōTERRA Wellness Advocates and customers. Through industry leading responsible sourcing practices, dōTERRA maintains the highest levels of quality, purity and sustainability in partnership with local growers around the world through Cō-Impact Sourcing®. The dōTERRA Healing Hands Foundation®, a registered 501(c)(3) non-profit organization, offers resources and tools to global sourcing communities and charitable organizations for self-reliance, healthcare, education, sanitation, and the fight against human trafficking. Through the life-enhancing benefits of essential oils, dōTERRA is changing the world one drop, one person, one community at a time. To learn more, visit www.doterra.com.

About RIFM

RIFM is the international scientific authority for the safe use of fragrance materials. RIFM generates, evaluates and distributes scientific data on the safety assessment of fragrance raw materials found in personal and household care products. Through extensive research, testing and constant monitoring of all scientific literature available, RIFM maintains its Database as the most comprehensive source worldwide of physical-chemical, toxicological and eco-toxicological data associated with known fragrance and flavor materials. RIFM’s scientific findings are evaluated by an independent Expert Panel—an international group of dermatologists, pathologists, toxicologists, reproduction, respiratory and environmental scientists. The Expert Panel evaluates the safety of fragrance ingredients under conditions of intended use and publishes its results in peer-reviewed scientific journals. The decisions of the Expert Panel regarding restrictions of use are published as IFRA Standards. For more information about RIFM, visit www.rifm.org.

Press Contact

Kevin Wilson
kawilson@doterra.com

doTERRA Becomes the First Global Aromatherapy and Essential Oils Company to Join Research Institute for Fragrance Materials

Partnership will pioneer advanced essential oil research

PLEASANT GROVE, Utah, June 17, 2020 (GLOBE NEWSWIRE) — doTERRA today announced that it has been accepted as a supporting member of the world-renowned Research Institute for Fragrance Materials (RIFM). As the leading global aromatherapy and essential oils company, doTERRA was granted membership based on a unanimous vote from the organization’s board of directors. RIFM also invited doTERRA scientists to contribute their essential oils’ knowledge and expertise as part of the organization’s natural complex substances working group.

RIFM’s purpose is to gather and analyze scientific data, engage in testing and evaluation, distribute information, cooperate with official agencies, and encourage uniform safety standards related to the use of fragrance ingredients.

“Our reputation for the relentless pursuit of purity fostered a relationship between RIFM and doTERRA’s sourcing team, which led to the decision to pursue membership in the organization,” said Dr. Russell J. Osguthorpe, doTERRA’s chief medical officer. “This partnership is part of an initiative to perform safety assessments on natural complex substances, such as essential oils. RIFM produces the most authoritative and comprehensive fragrance safety evaluations in the world. Together, we will improve the worldwide understanding of the science and safety behind essential oils, as well as their uses aromatically, topically and internally.”

As members, doTERRA will have access to RIFM’s comprehensive database on fragrance and flavor ingredients, which provides upwards of 70,000 references that include more than 135,000 human health and environmental studies on more than 6,000 materials.

An independent expert scientific panel reviews all of RIFM’s research, and its conclusions form the basis for the standards set by the International Fragrance Association (IFRA). Using the most current, globally-recognized guidelines, RIFM has to date completed panel-approved safety assessments for more than 85% of the current volume of use by the fragrance industry.

“We are an organization that firmly believes that we can do so much better with the safety and understanding of natural complex substances when we bring more resources to the table and expert voices to the discussion,” said RIFM’s President, James C. Romine, PhD. “doTERRA offers a unique and valuable perspective to RIFM, and we look forward to its scientists’ ongoing contributions to our working group.”

About doTERRA

dōTERRA® International is an integrative health and wellness company and the world leader in the Global Aromatherapy and Essential Oils market. dōTERRA sources, tests, manufactures and distributes CPTG Certified Pure Therapeutic Grade® essential oils and essential oil products to over eight million dōTERRA Wellness Advocates and customers. Through industry leading responsible sourcing practices, dōTERRA maintains the highest levels of quality, purity and sustainability in partnership with local growers around the world through Cō-Impact Sourcing®. The dōTERRA Healing Hands Foundation®, a registered 501(c)(3) non-profit organization, offers resources and tools to global sourcing communities and charitable organizations for self-reliance, healthcare, education, sanitation, and the fight against human trafficking. Through the life-enhancing benefits of essential oils, dōTERRA is changing the world one drop, one person, one community at a time. To learn more, visit www.doterra.com.

About RIFM

RIFM is the international scientific authority for the safe use of fragrance materials. RIFM generates, evaluates and distributes scientific data on the safety assessment of fragrance raw materials found in personal and household care products. Through extensive research, testing and constant monitoring of all scientific literature available, RIFM maintains its Database as the most comprehensive source worldwide of physical-chemical, toxicological and eco-toxicological data associated with known fragrance and flavor materials. RIFM’s scientific findings are evaluated by an independent Expert Panel—an international group of dermatologists, pathologists, toxicologists, reproduction, respiratory and environmental scientists. The Expert Panel evaluates the safety of fragrance ingredients under conditions of intended use and publishes its results in peer-reviewed scientific journals. The decisions of the Expert Panel regarding restrictions of use are published as IFRA Standards. For more information about RIFM, visit www.rifm.org.

Press Contact

Kevin Wilson
kawilson@doterra.com

Informa Pharma Intelligence Names Ramsey Hashem As President

Former Chief Commercial Officer Assumes Role Today

LONDON, June 17, 2020 (GLOBE NEWSWIRE) — Informa Pharma Intelligence, the global business intelligence leader for the biopharma industry, today announced that, effective July 1, Ramsey Hashem, Informa Pharma Intelligence’s Chief Commercial Officer, has been named President. Hashem will assume the role from Linda Blackerby, who is moving into non-executive roles after 11 years of successful service leading business units at Informa.

As President and CEO, Hashem will be responsible for overseeing the entire Global Pharma Intelligence operations as well as launching new intelligence products to support the pharmaceutical industry’s needs for more data-driven decisions. Hashem brings over 25 years of experience at companies like Thomson Reuters, Clarivate Analytics, Wolters Kluwer Health and GE Healthcare, as well as managing and directing commercial success for analytic product launches. In his role as CCO of Informa Pharma Intelligence, he’s been responsible for the company’s revenue and sales goals and implementing customer engagement into the organization’s workflow.

The transition to Hashem builds on Informa Pharma Intelligence’s recent success – including the launch of a COVID-19 content hub, designed to provide key information related to the global outbreak, and a recent partnership with Signals Analytics, to provide data helping uncover trends and novel insights for life sciences companies mitigating investment risk and accelerating the drug development process.

“I’ve worked with Ramsey for the past 3 years, and I strongly feel he has the right experience, track record and skills to lead our business forward,” said Linda Blackerby, Informa Pharma Intelligence’s outgoing President. “His keen understanding of building and motivating teams to drive customer-centric results, and his experience collaborating across teams to drive real, tangible results will deliver continued success for Informa Pharma Intelligence. I have witnessed firsthand his ability to create a balanced work environment for his employees to perform at their best by fostering trust, collaboration and creativity.”

“I’ve been in the information business my entire career.  I have always valued Informa Pharma Intelligence’s commitment to providing innovative solutions to businesses in the biopharma industry. The work we’ve been able to accomplish has led to drastic change and progress in how pharmaceutical companies develop effective treatments,” said Ramsey Hashem, Informa Pharma Intelligence, President.  “Linda has been an outstanding leader as President and CEO of Pharma Intelligence, and I’m looking forward to continuing her legacy of building relationships with our industry partners and customers and gaining additional industry recognition.”

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products—Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

Media Contacts:
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com
646.571.0120

 

Informa Pharma Intelligence Names Ramsey Hashem As President

Former Chief Commercial Officer Assumes Role Today

LONDON, June 17, 2020 (GLOBE NEWSWIRE) — Informa Pharma Intelligence, the global business intelligence leader for the biopharma industry, today announced that, effective July 1, Ramsey Hashem, Informa Pharma Intelligence’s Chief Commercial Officer, has been named President. Hashem will assume the role from Linda Blackerby, who is moving into non-executive roles after 11 years of successful service leading business units at Informa.

As President and CEO, Hashem will be responsible for overseeing the entire Global Pharma Intelligence operations as well as launching new intelligence products to support the pharmaceutical industry’s needs for more data-driven decisions. Hashem brings over 25 years of experience at companies like Thomson Reuters, Clarivate Analytics, Wolters Kluwer Health and GE Healthcare, as well as managing and directing commercial success for analytic product launches. In his role as CCO of Informa Pharma Intelligence, he’s been responsible for the company’s revenue and sales goals and implementing customer engagement into the organization’s workflow.

The transition to Hashem builds on Informa Pharma Intelligence’s recent success – including the launch of a COVID-19 content hub, designed to provide key information related to the global outbreak, and a recent partnership with Signals Analytics, to provide data helping uncover trends and novel insights for life sciences companies mitigating investment risk and accelerating the drug development process.

“I’ve worked with Ramsey for the past 3 years, and I strongly feel he has the right experience, track record and skills to lead our business forward,” said Linda Blackerby, Informa Pharma Intelligence’s outgoing President. “His keen understanding of building and motivating teams to drive customer-centric results, and his experience collaborating across teams to drive real, tangible results will deliver continued success for Informa Pharma Intelligence. I have witnessed firsthand his ability to create a balanced work environment for his employees to perform at their best by fostering trust, collaboration and creativity.”

“I’ve been in the information business my entire career.  I have always valued Informa Pharma Intelligence’s commitment to providing innovative solutions to businesses in the biopharma industry. The work we’ve been able to accomplish has led to drastic change and progress in how pharmaceutical companies develop effective treatments,” said Ramsey Hashem, Informa Pharma Intelligence, President.  “Linda has been an outstanding leader as President and CEO of Pharma Intelligence, and I’m looking forward to continuing her legacy of building relationships with our industry partners and customers and gaining additional industry recognition.”

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products—Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

Media Contacts:
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com
646.571.0120

 

Novavax Announces Additions to Executive Leadership

Dr. Filip Dubovsky appointed SVP, Chief Medical Officer Silvia Taylor appointed SVP, Investor Relations and Corporate Affairs

GAITHERSBURG, Md., June 17, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of two senior executives to the leadership team. Filip Dubovsky, M.D., MPH, FAAP, has been appointed Senior Vice President and Chief Medical Officer, where he will oversee Novavax’ medical and clinical affairs and related activities. Novavax also appointed Silvia Taylor, MBA, as Senior Vice President, Investor Relations and Corporate Affairs, overseeing Novavax’ investor relations, public relations and corporate communications activities.

“Novavax’ considerable progress and significant near-term milestones make the additions of Filip and Silvia to our leadership team both timely and important,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With the addition of these two senior leaders, we are adding expertise to critical areas of the organization. We welcome them both.”

A recognized leader in vaccine development, Dr. Dubovsky brings more than 20 years of infectious disease experience to Novavax. He joins Novavax from AstraZeneca, where he was Head of Clinical Engagement and Policy and Deputy Chief Medical Officer for clinical affairs. He joined MedImmune, the global biologics arm of AstraZeneca, where he oversaw the clinical development of early and late-stage infectious disease and vaccine assets. Previously, he created and managed a portfolio of 25 malaria vaccine candidates spanning early candidate optimization to Phase 3 clinical studies at PATH’s Malaria Vaccine Initiative. He has co-authored more than 50 peer-reviewed scientific publications and currently sits on the Board of Directors of the Sabin Institute. Dr. Dubovsky earned his Master of Public Health degree from Johns Hopkins University and his Doctor of Medicine degree from the University of Alabama. He completed his pediatric training at Stanford University, his pediatric infectious disease fellowship at the Center for Vaccine Development at the University of Maryland, and his preventive medicine training at Johns Hopkins University.

“The recent scientific achievements by the Novavax team, including positive Phase 3 NanoFlu results and Phase 1/2 clinical trial initiation of NVX-CoV2373 to address the global coronavirus pandemic are impressive,” said Dr. Dubovsky. “I am eager to put my experience to work to help Novavax deliver these novel vaccines to healthcare practitioners and reduce the spread of these harmful diseases worldwide.”

Ms. Taylor brings more than 25 years of communications and commercial leadership to Novavax. Most recently, she was Vice President of Global Corporate Affairs and Communications at Autolus Therapeutics plc, where she led all financial, scientific and corporate communications. Prior to Autolus, Ms. Taylor was Senior Vice President of Global Investor Relations and Corporate Affairs at Sucampo. Earlier in her career, she held positions of increasing responsibility at MedImmune, the global biologics arm of AstraZeneca, including head of marketing responsible for the commercialization of the company’s respiratory syncytial virus and influenza franchises, as well as roles at Pfizer, where she served in key brand and consumer marketing roles. She has also worked in public relations and communications roles in agency and non-profit settings. Ms. Taylor earned a Master of Business Administration degree from Columbia University and a Bachelor of Arts in Foreign Affairs from University of Virginia.

“I am delighted to join Novavax during this incredibly productive period,” said Ms. Taylor. “It is an exciting opportunity to help tell the company’s compelling story as it brings innovative vaccines to patients, and to help deepen Novavax’ relationships with a broad array of important stakeholders.”

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:
Investors
Novavax, Inc.
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659